Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs
There are several challenges towards the development and clinical use of small molecule inhibitors, which are currently the main type of targeted therapies towards intracellular proteins. PROteolysis-TArgeting Chimeras (PROTACs) exploit the intracellular ubiquitin-proteasome system to selectively de...
Main Authors: | Sainan An, Liwu Fu |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2018-10-01
|
Series: | EBioMedicine |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2352396418303621 |
Similar Items
-
Non-small molecule PROTACs (NSM-PROTACs): Protein degradation kaleidoscope
by: Sinan Ma, et al.
Published: (2022-07-01) -
Targeted Protein Degradation by Chimeric Small Molecules, PROTACs and SNIPERs
by: Mikihiko Naito, et al.
Published: (2019-12-01) -
Small-Molecule PROTACs for Cancer Immunotherapy
by: Zefan Liu, et al.
Published: (2022-08-01) -
Protein degradation induced by PROTAC molecules as an emerging drug discovery strategy
by: Koravović Mladen, et al.
Published: (2022-01-01) -
An overview of PROTACs: a promising drug discovery paradigm
by: Zi Liu, et al.
Published: (2022-12-01)